IFR US ECM Calendar
October 23: X4 Pharmaceuticals (US, biotech) ─ $125m ABB. Fixed size (Primary) marketed at $2.85-$2.95 versus $3.09 last sale. LEER, STFL, GUGG. Wall cross. Offering includes pre-funded warrants.
October 26: MapLight Therapeutics (US, biotech) – $250.8m IPO. 14.8m shares (Primary) at $17.00 fixed price. MS, JEFF, LEER, STFL. Nasdaq "MPLT". T. Rowe Price indicated for $40m of offering. Goldman Sachs affiliate investing $8.1m through a concurrent private placement.
October 29: Navan (US, software) – $960m IPO. 36.9m shares (Primary, Secondary) at $24-$26. GS, CITI. Nasdaq “NAVN”. Selling shareholders led by co-founders Ariel Cohen and Ilan Twig.
November 3: Beta Technologies (US, EV aircraft) – $825m IPO. 25m shares (Primary) at $27-$33. MS, GS. NYSE “BETA”. Alliance Bernstein, BlackRock, company director Chuck Davis, GE Aerospace and Federated have indicated for $300m combined of offering. 5% DSP.
November 4: Exzeo Group (US, insurtech) ─ $176m IPO. 8m shares (Primary) at $20-$22. TRST, CITZ, WBLR. NYSE “XZO”. Pricing date based on automatic effectiveness 20 days from 10/16 S-1/A filing. Spin-off from HCI Group. 5% DSP.
November 5: Grupo Aeromexico (Mexico, airline) ─ $234.5m IPO. 11.7m ADSs (Primary, Secondary) at $18-$20. BARC, MS, JPM, EVER. NYSE “AERO”. PAR Investment Partners investing $25m in a concurrent private placement. Apollo Global and Strategic Value Partners are among the selling shareholders. Emerged from bankruptcy in March 2022.
November 5: BillionToOne (US, diagnostics) ─ $211.5m IPO. 3.8m shares (Primary) at $49-$55. JPM, PJ, JEFF, WBLR. Nasdaq “BLLN”. 5% DSP. Pricing date based on automatic effectiveness 20 days from 10/17 S-1/A filing.
November 6: Evommune (US, biotech) ─ $159.4m IPO. 9.4m shares (Primary) at $15-$17. MS, LEER, EVER, CANT. NYSE "EVMN". Pricing date based on automatic effectiveness 20 days from 10/17 S-1/A filing.
November 10: Public Policy (US, public affairs) ─ $60m Nasdaq IPO. 4.1m shares (Primary, Secondary) versus $14.64 reference price at launch. OPCO, CGEN. Nasdaq “PPHC”. Cross-listing of common shares trading on LSE AIM market under the symbol “PPHC” at £10.90 ($14.64) at launch. Pricing date based on automatic effectiveness 20 days from 10/21 S-1/A filing.